Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus
Global Malignant Pleural Effusion Market Will Surge At 6% CAGR And Reach USD 8.06 Billion By 2033
The global malignant pleural effusion market will likely reach a valuation of USD 8.06 billion by 2033, rising from USD 4.5 billion in 2023. The market is slated to grow at a positive CAGR of 6% from 2023 to 2033. This growth can be attributed to rising incidences of pleural effusion disorder as well as a growing awareness of progressive pleural effusion treatments with different types of techniques. Increasing awareness of health and wellness, and advancements in diagnosis techniques and pathology, especially in developing countries, will drive the therapeutics market. Further, increasing research and development efforts to produce novel therapeutics as well as improve the efficacy of existing ones also drive the market growth.
Historically, the market observed a CAGR of 4% from 2018 to 2022 and is projected to demonstrate fair growth over the forecast period. Malignant pleural effusion is a common complication in various cancer cases. It causes shortness of breath and discomfort in the chest. Pleural effusion forms when cells from a type of cancer spread to the pleural space. These cancer cells amplify the production of pleural fluid and cause reduced absorption of the fluid. Increasing cases of tumors of the heart, lungs, and breast propel the malignant pleural effusion market forward. An upsurge in research efforts and the introduction of newer drug regimes that present improved overall survival rates including delaying neurological deterioration.
Track the Latest Market Developments: Request a Sample Report! Https://www.Futuremarketinsights.Com/report-sample#5245502d47422d3136323330
Increasing initiatives by government and private organizations, alike, including agencies like WHO and pharmaceutical enterprises, to generate awareness regarding pleural effusions will drive market growth. High incidences of malignant pleural effusions, however, are the key driver of the market. Moreover, a report published in 2022 revealed that pleural effusion is related to the risk and prognosis of COVID-19. Thus, the pandemic also amplified the cases of pleural effusions which, in turn, fueled the growth of the malignant pleural effusion market. Though the market is predicted to undergo positive growth during this period, it will also face certain challenges. High costs of treatment, lack of awareness of the disease, and insufficient treatment options will stymie the growth of the malignant pleural effusion market.
Key Takeaways
Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends! Https://www.Futuremarketinsights.Com/reports/malignant-pleural-effusion-market
Competitive Landscape
Allakos, iCo Therapeutics, Akari Therapeutics, and Santen, among others, are a few of the main participants in the malignant pleural effusion market profiled in the full version of the report.
Noteworthy developments include the September 2021 launch of BIAPENEM by BDR Pharma. This drug is used to treat intra-abdominal infections, lower respiratory tract infections, and complicated urinary tract infections. Notably, Biapenem demonstrates effective distribution and penetration into various tissues and fluids, including lung tissue, sputum, pleural effusion, and abdominal cavity fluid.
Additionally, in April 2022, a clinical study titled "IFN-γ Combined with T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites" was registered on ClinicalTrials.Gov, highlighting ongoing research efforts to improve treatment options for this condition.
Key Segments Profiled in the Malignant Pleural Effusion Industry Survey
By Diagnosis:
By End User:
By Treatment:
By Region:
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-347-918-3531For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube
Vitamins By Condition
Learn about User Reviews and read IMPORTANT information about user generated content
Conditions of Use and Important Information: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.
Medications And Drugs For Treatment Of Pleural Effusion
Pleural effusion is the accumulation of fluid in the space between the two coverings (pleura) of the lung. The ability of the lung to expand is affected.
PhosphocolPhosphocol is a diagnostic agent, prescribed for peritoneal or pleural effusions.
Comments
Post a Comment